Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Roche and Lilly's Alzheimer's Blood Test Gains FDA Approval, Marking Milestone in Diagnostics

Roche and Lilly's Alzheimer's Blood Test Gains FDA Approval, Marking Milestone in Diagnostics

In a significant development for Alzheimer's disease diagnostics, Roche and Eli Lilly have secured FDA clearance for their blood-based biomarker test, Elecsys pTau181. This approval marks a crucial step forward in the early detection and management of Alzheimer's disease, potentially accelerating patient access to emerging therapies.

NoahAI News10/15/2025
Boehringer Ingelheim and Click Therapeutics' Digital Therapeutic Shows Promise in Schizophrenia Trial

Boehringer Ingelheim and Click Therapeutics' Digital Therapeutic Shows Promise in Schizophrenia Trial

German pharmaceutical giant Boehringer Ingelheim and digital therapeutics company Click Therapeutics have announced positive results from their phase 3 trial of a novel digital therapeutic for schizophrenia. The investigational prescription digital therapeutic (PDT), known as CT-155, has met its primary endpoint in addressing negative symptoms of the condition, marking a significant milestone in the treatment of this complex mental health disorder.

NoahAI News10/15/2025
Pharmaceutical Industry Roundup: AstraZeneca's Pricing Deal, Novo Nordisk's Setbacks, and Novavax's Uncertain Future

Pharmaceutical Industry Roundup: AstraZeneca's Pricing Deal, Novo Nordisk's Setbacks, and Novavax's Uncertain Future

AstraZeneca has become the second major pharmaceutical company to reach a drug pricing agreement with the Trump Administration. Following Pfizer's recent deal, AstraZeneca has agreed to sell its drugs to Medicaid at a discount and participate in a new government website offering lower cash prices for medications. The agreement also delays potential tariffs on AstraZeneca drugs by three years. This move, while significant for government programs, does not affect those with commercial insurance or those who don't pay out of pocket.

NoahAI News10/15/2025
Pfizer's Tukysa Shows Promise in HER2-Positive Breast Cancer Maintenance Therapy

Pfizer's Tukysa Shows Promise in HER2-Positive Breast Cancer Maintenance Therapy

Pfizer has announced positive results from a phase 3 trial of Tukysa, a HER2-targeted tyrosine kinase inhibitor, potentially expanding its use into first-line maintenance therapy for HER2-positive metastatic breast cancer. This development marks another significant advancement in Pfizer's oncology portfolio, following the company's $43 billion acquisition of Seagen.

NoahAI News10/15/2025
BioCryst Pharmaceuticals to Acquire Astria Therapeutics in $700 Million Deal, Expanding Hereditary Angioedema Portfolio

BioCryst Pharmaceuticals to Acquire Astria Therapeutics in $700 Million Deal, Expanding Hereditary Angioedema Portfolio

BioCryst Pharmaceuticals has announced its intention to acquire Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million. The acquisition, which is expected to close in the first quarter of 2026, centers around an experimental hereditary angioedema (HAE) medicine currently in late-stage testing.

NoahAI News10/15/2025
Lila Sciences Secures Additional $115M in Series A Funding, Bringing Total to $350M

Lila Sciences Secures Additional $115M in Series A Funding, Bringing Total to $350M

Flagship Pioneering's Lila Sciences has significantly expanded its Series A funding round, adding $115 million to bring the total raised to $350 million. This latest influx of capital includes backing from Nvidia's venture arm, NVentures, further solidifying Lila's position at the intersection of artificial intelligence and biotechnology.

NoahAI News10/15/2025
Johnson & Johnson to Spin Off Orthopedics Business, Focuses on High-Growth Medtech Sectors

Johnson & Johnson to Spin Off Orthopedics Business, Focuses on High-Growth Medtech Sectors

Johnson & Johnson (J&J) announced plans to spin out its orthopedics business, DePuy Synthes, into a standalone company within the next 18 to 24 months. This strategic move aims to sharpen J&J's focus on higher-growth medical technology sectors, particularly cardiovascular and robotic surgery.

NoahAI News10/15/2025
Precision Medicine Startup Radence Launches Comprehensive Health Monitoring Service

Precision Medicine Startup Radence Launches Comprehensive Health Monitoring Service

Radence, a new precision medicine startup, has entered the healthcare technology space with a bold promise: early disease detection and prevention through advanced diagnostics and personalized health monitoring. The company, which describes its offering as "concierge science," aims to provide a 360-degree view of an individual's health using a combination of cutting-edge technologies and data analysis.

NoahAI News10/15/2025
Kailera Therapeutics Secures $600M for Obesity Drug Development, Joining Industry Giants in Weight Loss Race

Kailera Therapeutics Secures $600M for Obesity Drug Development, Joining Industry Giants in Weight Loss Race

Kailera Therapeutics has successfully raised $600 million in a Series B funding round, marking one of the largest financial injections in the pharmaceutical industry this year. The biotechnology company plans to use this substantial investment to advance its pipeline of weight-loss therapies, with a particular focus on launching a global Phase III program for its lead asset, KAI-9531.

NoahAI News10/14/2025
FDA Approves First Alzheimer's Blood Test for Primary Care Use

FDA Approves First Alzheimer's Blood Test for Primary Care Use

Roche and Eli Lilly have secured FDA approval for Elecsys pTau181, the first blood-based test for Alzheimer's disease assessment approved for use in primary care settings. This landmark decision, announced on October 14, 2025, marks a significant advancement in the early detection and management of Alzheimer's disease.

NoahAI News10/14/2025
Johnson & Johnson to Spin Out Orthopedics Business, Focusing on High-Growth Medical Technology Sectors

Johnson & Johnson to Spin Out Orthopedics Business, Focusing on High-Growth Medical Technology Sectors

Johnson & Johnson (J&J) has announced plans to spin out its orthopedics business, creating a standalone company that will operate under the name DePuy Synthes. This strategic move, expected to be completed within the next 18 to 24 months, aims to sharpen J&J's focus on higher-growth and higher-margin medical technology markets.

NoahAI News10/14/2025
BioCryst Acquires Astria Therapeutics in $700M Deal, Aiming to Revolutionize HAE Treatment

BioCryst Acquires Astria Therapeutics in $700M Deal, Aiming to Revolutionize HAE Treatment

BioCryst Pharmaceuticals has announced a significant move in the rare disease market with its $700 million acquisition of Astria Therapeutics. This strategic buyout positions BioCryst to challenge Takeda's dominance in the hereditary angioedema (HAE) therapy space, particularly with its phase 3 candidate navenibart.

NoahAI News10/14/2025
«1...232425...67»